Clinical Trials Logo

Fallopian Tubes Cancer clinical trials

View clinical trials related to Fallopian Tubes Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT01767675 Active, not recruiting - Ovarian Cancer Clinical Trials

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Start date: January 8, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if the investigators can improve the treatment of this type of cancer. They want to find out what effects, good and/or bad, giving heated chemotherapy into the belly, known as hyperthermic intraperitoneal chemotherapy (HIPEC), has on the patient and this type of cancer. The goal of HIPEC is to expose any cancer left in the abdomen after surgery to high doses of chemotherapy. The chemotherapy is heated in the hope that this will make it easier for it to get into and kill the cancer cells. The drug used for HIPEC will be carboplatin, a Food and Drug Administration (FDA) approved drug for use in ovarian, fallopian tube or primary peritoneal cancer.

NCT ID: NCT01223235 Completed - Ovarian Cancer Clinical Trials

Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab

Start date: October 2010
Phase: N/A
Study type: Interventional

The immune system of the body has the ability to fight and eliminate infections and cancers. Immune treatments, such as in this study, seek to teach the immune system to find and destroy cancer cells. The purpose of this study is to test whether it is safe to treat the cancer with a vaccine and another drug called bevacizumab (also known as Avastin).